These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32694051)

  • 1. The pros and cons of interferons for oncolytic virotherapy.
    Geoffroy K; Bourgeois-Daigneault MC
    Cytokine Growth Factor Rev; 2020 Dec; 56():49-58. PubMed ID: 32694051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses.
    Matveeva OV; Chumakov PM
    Rev Med Virol; 2018 Nov; 28(6):e2008. PubMed ID: 30209859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
    Feola S; Russo S; Ylösmäki E; Cerullo V
    Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.
    Marelli G; Howells A; Lemoine NR; Wang Y
    Front Immunol; 2018; 9():866. PubMed ID: 29755464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.
    Shen Z; Liu X; Fan G; Na J; Liu Q; Lin F; Zhang Z; Zhong L
    J Transl Med; 2023 Nov; 21(1):842. PubMed ID: 37993941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.
    Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
    Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189110. PubMed ID: 38754793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y; Xie D; Yang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in targeting cancer stem cells using oncolytic viruses.
    Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
    Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic viruses and immunity.
    Chaurasiya S; Chen NG; Fong Y
    Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.
    Wang S; Wei J
    Int J Cancer; 2022 Nov; 151(10):1654-1662. PubMed ID: 35633046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
    Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
    Front Immunol; 2022; 13():950079. PubMed ID: 36703982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gamble between oncolytic virus therapy and IFN.
    Li Q; Tan F; Wang Y; Liu X; Kong X; Meng J; Yang L; Cen S
    Front Immunol; 2022; 13():971674. PubMed ID: 36090998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses.
    Bifulco M; Di Zazzo E; Napolitano F; Malfitano AM; Portella G
    Biochimie; 2023 Mar; 206():89-92. PubMed ID: 36273765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.